#### Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY BIO Form 4 October 04, 2	PHARMA INC											
									OMB A	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	Number:3235-0287Number:January 31, 2005Expires:2005Estimated average burden hours per response0.5			
Section 16. Form 4 or Form 5 obligations may continue. Filed pursuant to Section 17(a) of the			F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940									
<i>See</i> Instru- 1(b).	ction	30(h) of t	the Inv	vestment (	Company	Act	of 194	+0				
(Print or Type R	esponses)											
1. Name and Address of Reporting Person <u>*</u> KOCH KEVIN			2. Issuer Name <b>and</b> Ticker or Trading Symbol ARRAY BIOPHARMA INC [ARRY]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 3200 WALNUT STREET			3. Date of Earliest Transaction (Month/Day/Year) 10/04/2011				_X_ Director10% Owner _X_ Officer (give title Other (specify below) President, CSO					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
BOULDER,	CO 80301							Form filed by M Person				
(City)	(State) (	Zip)	Table	e I - Non-De	erivative S	ecurit	ies Acc	es Acquired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/	ate, if	Code	n(A) or Dis (D)	posed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial		
Common Stock	10/04/2011			А	50,271 (1)	А	\$0	752,236	D			
Common Stock								43,286	I	Held By Spouse		
Common Stock								99,000	I	Held in trust for children		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form (9-02)

#### Edgar Filing: ARRAY BIOPHARMA INC - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	″ (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
1	Director	10% Owner	Officer	Other				
KOCH KEVIN 3200 WALNUT STREET BOULDER, CO 80301	X President, CSO							
Signatures								
R. Michael Carruthers, attorney Person	,	10/04/2011						
**Signature of Repor		Date						

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These fully vested shares were issued as a bonus pursuant to the fiscal 2011 Performance Bonus Program and the Array BioPharma Inc. Amended and Restated Stock Option and Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.